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SHORT COMMUNICATION
First prenatal molecular diagnosis in a family with
holocarboxylase synthetase deficiency
Sabrina Malvagia, Amelia Morrone, Elisabetta Pasquini, Silvia Funghini, Giancarlo la Marca, Enrico
Zammarchi* and Maria Alice Donati
Metabolic and Muscular Unit, Department of Pediatrics, University of Florence, Meyer Children’s Hospital, Florence, Italy
Objectives We report on the first prenatal molecular diagnosis of holocarboxylase synthetase (HLCS)
deficiency in the fourth pregnancy of an at-risk family. This disorder is a rare autosomal recessive inborn
error of metabolism, leading to a multiple carboxylase defect (MCD). HLCSD diagnosis was performed
postmortem in the proband on DNA from autoptic biological material. Molecular analysis of the proband’s
entire HLCS gene by direct sequencing identified the R508W amino acid change, at the homozygous status.
Methods Fetal DNA was isolated from chorionic villus sampling at 11 weeks of gestation. Direct sequencing
of exon 6 of the fetal HLCS gene was performed.
Results The R508W mutation was identified in the fetal DNA at the homozygous level. The genetic lesion
was confirmed on abortive tissue.
Conclusion Molecular diagnosis has several advantages over enzymatic activity assay of carboxylases in
chorionic villi or amniocytes. It can be performed earlier, is faster, and the response time is shorter. Copyright
 2005 John Wiley & Sons, Ltd.
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INTRODUCTION
Holocarboxylase synthetase (HLCS) deficiency (MIM
253270) is a rare autosomal recessive inborn error
of metabolism leading, as with biotinidase deficiency
(MIM 253260), to a multiple carboxylase defect (MCD).
Nutritional biotin deficiency (Sweetman et al., 1981) and
biotin transport defects can also cause MCD (Mardach
et al., 2002).
Most patients with holocarboxylase synthetase defi-
ciency (HLCSD) present early in life with feeding and
respiratory difficulties, vomiting, hypotonia, seizures,
lethargy, and coma (Narisawa et al., 1982; Wolf, 2000).
In these patients, rapid diagnosis and treatment is neces-
sary to avoid death. However, HLCSD can also be late
onset. Some patients also exhibit skin lesions and ery-
thematous rash, hair loss, as well as developmental delay
(Wolf, 2000). The main laboratory findings are metabolic
acidosis, lactic acidosis, ketosis, hyperammonemia, and
organic aciduria showing a typical urinary excretion pat-
tern (Nyhan and Ozand, 1998). Clinical and biochemical
findings usually improve markedly following treatment
with pharmacological doses of biotin, but some patients
have been reported as only partially biotin responsive
(Wolf et al., 1981; Suormala et al., 1997; Morrone et al.,
2002).
*Correspondence to: Enrico Zammarchi, Department of Pediatrics,
Meyer Children’s Hospital, Via Luca Giordano 13, 50132 Flo-
rence, Italy. E-mail: zammarchi@unifi.it
Determination of the HLCS gene’s genomic orga-
nization (Morrone et al., 2002) makes molecular and
prenatal diagnosis easy.
We report on a prenatal diagnosis in an Iranian
family. Two children had previously died in a local
hospital without being diagnosed. HLCSD diagnosis
was made postmortem in the second affected child
using autoptic biological material. The R508W amino
acid change, a common mutation in several ethnic
groups (Dupuis et al., 1996; Sakamoto et al., 1998;
Hwu et al., 2000; Tang et al., 2003), was found at
the homozygous status in the sample (Morrone et al.,
2002).
FAMILY HISTORY
The patient, a male, was born to first-cousin Iranian
parents after an uneventful pregnancy and delivery
(Figure 1). His sister was normal. The second child of
the family died at 6 months of age without diagnosis, but
with the same symptoms as the proband. The patient was
well until 6 months after birth, when he was admitted
to a local hospital for respiratory distress, drowsiness,
lethargy, and, subsequently, coma with severe metabolic
acidosis (pH 7.09) and a very high anion Gap (32).
He died a few days later. Biological fluids and autop-
tic material were collected and shipped to our center.
GC/MS analysis, performed postmortem, showed a typ-
ical MCD urinary organic acid pattern with elevated
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Figure 1—Family pedigree. The symbols without a line on top
represent family members not available for biochemical or genetic
testing. Black symbols represent affected individuals. Shaded figures
indicate a possibly affected individual. Carriers are represented with
a single dot inside the symbol. An arrow indicates the proband
excretions of 3-hydroxypropionate 448 mmol/molcreat
(n.v. <10), 3-methylcrotonylglycine 333 mmol/molcreat
(n.v. <2), 3-hydroxyisovalerato 61 mmol/molcreat (n.v.
<46), methylcitrate 15 mmol/molcreat (n.v. trace), pro-
pionylglycine 131 mmol/molcreat (n.v. <2), tiglylgly-
cine 198 mmol/molcreat (n.v. <2) and lactate 4948
mmol/molcreat (n.v. <259). Plasma biotinidase activity
was a normal 6.2 nmol/min/mL (n.v. 6.3–10.54).
Genetic analysis of DNA from autoptic liver tissue
demonstrated that the patient was homozygous for the
known R508W mutation due to the transition c1522C >
T in exon 6 of the HLCS gene (Morrone et al., 2002).
Enzymatic restriction analysis confirmed the mutation at
a heterozygous level in both parents, while his healthy
sister was not a carrier.
With the aim of making a prenatal diagnosis in
the couple’s fourth pregnancy, DNA was isolated
from chorionic villus sampling at 11 weeks of gesta-
tion. Direct sequencing of exon 6 in the fetal HLCS
gene identified the R508W mutation at the homozy-
gous level. Organic acid analysis of methylcitric and
3-hydroxyisovaleric acid in the selected ion monitoring
(SIM) mode using, for methylcitric acid, the stable iso-
tope dilution method, was also performed on 0.5 mL of
amniotic fluid obtained during villocentesis. The results
were not informative (methylcitric acid 0.49 µM, normal
control 0.55 µM; 3-hydroxyisovaleric acid not detected).
We advised the parents that in all reported cases this
mutation has been associated with biotin responsiveness,
but they decided to interrupt the pregnancy.
The genetic lesion was confirmed on abortive tissue
at the homozygous level.
DISCUSSION
The R508W mutation, mapped within the biotin-binding
domain, has been reported in several other patients at
the homozygous level (Dupuis et al., 1996; Hwu et al.,
2000; Tang et al., 2003). It has been associated with
the biotin-responsive and late-onset form of HLCSD,
according to the age of our patient and his brother
at presentation (6 months). Unfortunately, both died
before HLCS diagnosis was made and biotin therapy
started. It is probable that the severity of their clinical
manifestations and early death were due to a lack of
appropriate therapy (Thuy et al., 1999a).
Prenatal diagnosis of HLCS deficiency can be made
by activity assay of carboxylases (propionyl CoA car-
boxylase, 3-methylcrotonyl CoA carboxylase, and pyru-
vate carboxylase) or of HLCS in cultured amniocytes or
in chorionic villous (Thuy et al., 1999a, b). The deter-
mination of methylcitric acid and/or 3-hydroxyisovaleric
acid in amniotic fluid at the 16th week of pregnancy by
stable isotope dilution techniques has also been used
(Jakobs et al., 1984). However, organic acid analysis of
amniotic fluid may be inconclusive in an affected fetus
(Suormala et al., 1998; Thuy et al., 1999a, b) and car-
boxylases activity assays in cultured villus or amniocytes
are subsequently required to confirm diagnosis. Enzy-
matic activity assay is time consuming and results take a
long time. Moreover, cells must be cultured in a biotin-
low medium to ensure that the deficiency is detected
(Suormala et al., 1997; Thuy et al., 1999a, b; Touma
et al., 1999).
As expected, the determination of methylcitric acid
and 3-hydroxyisovaleric acid levels at the 11th week of
gestation, performed significantly earlier than the tradi-
tional 16–19 weeks, did not yield informative results.
Knowledge of the HLCS gene’s genomic organization
has lead to the development of a much faster and more
certain means of diagnosis via chorionic villus sampling
at 10–11 weeks of pregnancy. Up to now (to our knowl-
edge), only a few HLCS prenatal diagnosis have been
described in the literature, all performed at a biochem-
ical level. This is the first prenatal molecular diagnosis
reported in a case of HLCSD. Clearly, prenatal molecu-
lar diagnosis has advantages over both the activity assay
of carboxylases and the determination of organic acids in
amniotic fluid as it can be performed earlier, is quicker,
and leads to an accurate diagnosis in a very short time.
Mutation detection in this disorder is a good diagnos-
tic means. To our knowledge, only one genetic lesion
(Glu42Asp) identified in the gene could complicate the
diagnosis, as an expression study showed the same activ-
ity as the wild type (Yang et al., 2001). In our proband,
no polymorphism was detected.
The parents decided to interrupt the pregnancy despite
the known association of the R508W mutation with
biotin responsiveness. They could have decided to con-
tinue the pregnancy, undergoing biotin therapy. How-
ever, reported data about prenatal treatment of HLCS
deficiency is controversial (Packman et al., 1982; Roth
et al., 1982). It may be that biotin treatment immedi-
ately after birth in affected newborns avoids metabolic
decompensation (Wolf, 2000).
We stress the importance of storing any biological
fluids, tissues, and/or autoptic materials in order to make
a postmortem biochemical and/or molecular diagnosis.
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The latter is necessary for carrier detection and, possibly,
prenatal diagnosis.
In the case of HLCSD, it is also very important to
keep cultured fibroblasts that can be used for testing
biotin responsiveness in vitro which could lead to more
accurate genetic counseling.
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